TriSalus Life Sciences, Inc. TLSI Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Boston ScientificBSX

-$30M-700%

Revenue$8.9M-2.9%

Gross profit$7.7M0.0%

Operating income-$8.4M-14.8%

Net income$1.5M+115%

EPS (diluted)$0.03+108%

Cash & equivalents$56.6M+324%

Total debt$33.1M+4.4%

Total equity$12.8M+137%

Total assets$71.0M+148%

Operating cash flow-$6.5M-44.0%

CapEx$141.0K-81.3%

Free cash flow-$6.6M-26.0%

Market cap$279.45M+49.6%

Enterprise value$255.97M+33.6%

P/S6.2×+1.0×

Gross margin85.1%-0.5pp

Operating margin-62.4%-16.8pp

Net margin-60.9%-13.4pp

FCF margin-45.2%-16.8pp

Return on equity253.3%—

Debt / equity2.6×—

Current ratio5.8×+3.6×

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is TriSalus Life Sciences, Inc.'s contingent consideration fair value adjustments?: TriSalus Life Sciences, Inc. (TLSI) reported contingent consideration fair value adjustments of -$7.4M in Q1 2026.
How has TriSalus Life Sciences, Inc.'s contingent consideration fair value adjustments changed year-over-year?: TriSalus Life Sciences, Inc.'s contingent consideration fair value adjustments decreased by 1002.7% year-over-year, from $820K to -$7.4M.